Cancer Institute Hospital of JFCR
Tokyo 1358550
9 studies enrolling now · 14 studies all time
What they study most
Advanced Solid Tumor, Bladder Cancer, Breast Cancer, Carcinoma, Non-Small-Cell Lung, Cervical Cancer, Colorectal Cancer, Colorectal Neoplasms, Endometrial Cancer, Endometrial Neoplasms, Esophageal Cancer, Follicular Lymphoma, Gastric Adenocarcinoma
Studies at this site
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors — Recruiting now
- A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers — Recruiting now
- Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer — Recruiting now
- Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) — Recruiting now
- A Study of LY4175408 in Participants With Advanced Cancer — Recruiting now
- FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 — Recruiting now
- A Study of LY4170156 in Participants With Selected Advanced Solid Tumors — Recruiting now
- Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors — Recruiting now
- A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) — Recruiting now
- A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors — Running, not enrolling
- Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer — Running, not enrolling
- Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) — Running, not enrolling
- A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06) — Running, not enrolling
- A Study of DS-8201a in Metastatic Breast Cancer Previously Treated With Trastuzumab Emtansine (T-DM1) — Stopped early